CSL Limited Stock Other OTC
Stocks
US12637N1054
Pharmaceuticals
OTC Markets Traded|
End-of-day quote
Other OTC
|
||
| - USD | - |
|
| Market Cap | 59.81B 52.09B 49.3B 44.79B 83.68B 5,728B 84.09B 587B 227B 2,911B 225B 220B 9,318B | P/E 2027 * |
20.6x | P/E 2028 * | 18.6x |
|---|---|---|---|---|---|
| Enterprise Value | 68.98B 60.08B 56.86B 51.67B 96.52B 6,606B 97B 677B 262B 3,357B 259B 253B 10,748B | EV / Sales 2027 * |
4.38x | EV / Sales 2028 * | 4.21x |
| Free-Float |
99.97% | Yield 2027 * |
2.4% | Yield 2028 * | 2.55% |
Last Transcript: CSL Limited
| Manager | Title | Age | Since |
|---|---|---|---|
Gordon Naylor
CEO | Chief Executive Officer | 63 | 2026-02-10 |
Ken Lim
DFI | Director of Finance/CFO | 52 | 2025-10-06 |
Mary Oates
COO | Chief Operating Officer | - | 2025-04-30 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 72 | 2018-10-16 | |
Brian McNamee
BRD | Director/Board Member | 70 | 2011-02-01 |
Carolyn Hewson
BRD | Director/Board Member | 71 | 2019-12-08 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.32% | +0.55% | +31.25% | -4.69% | 78.83B | |
| -1.11% | +3.59% | -12.67% | -34.40% | 60.48B | |
| -2.01% | +7.97% | +510.81% | +49.27% | 63.11B | |
| +0.14% | -1.76% | -10.86% | +24.38% | 46.75B | |
| +0.43% | +1.90% | +2.95% | +152.71% | 45.66B | |
| -0.65% | +0.17% | +51.25% | -14.13% | 32.37B | |
| +0.39% | +4.92% | +48.20% | +114.17% | 25.87B | |
| +0.47% | +2.38% | +0.10% | +146.43% | 21.33B | |
| -0.47% | +2.01% | +62.26% | +102.90% | 15.8B | |
| Average | -0.35% | +3.40% | +75.92% | +59.63% | 43.35B | |
| Weighted average by Cap. | -0.52% | +3.94% | +95.98% | +41.05% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 15.77B 13.73B 13B 11.81B 22.06B 1,510B 22.17B 155B 59.86B 767B 59.22B 57.91B 2,456B | 16.31B 14.21B 13.45B 12.22B 22.82B 1,562B 22.94B 160B 61.93B 794B 61.28B 59.91B 2,542B |
| Net income | 2.82B 2.46B 2.33B 2.11B 3.95B 270B 3.97B 27.72B 10.72B 137B 10.61B 10.37B 440B | 3.16B 2.75B 2.6B 2.37B 4.42B 303B 4.44B 31.02B 11.99B 154B 11.87B 11.6B 492B |
| Net Debt | 9.18B 7.99B 7.56B 6.87B 12.84B 879B 12.9B 90.1B 34.84B 447B 34.47B 33.71B 1,430B | 8.86B 7.71B 7.3B 6.63B 12.39B 848B 12.45B 86.95B 33.62B 431B 33.27B 32.53B 1,380B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
